Labor & delivery. Pregnancy: monitor. Nursing mothers. Do not initiate Advair HFA with acutely deteriorating asthma; use in this setting is inappropriate. Not for relief of acute symptoms ...

The program will be implemented by January 1, 2025. The medicines in scope are Advair Diskus, Advair HFA, Anoro Ellipta, Arnuity Ellipta, Breo Ellipta, Incruse Ellipta, Serevent Diskus ...

Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...

A Nebraska pharmacist sentenced last fall for dispensing generic medications for name-brand drugs or processing claims ...

GSK said in the first quarter of 2024, the sales of Specialty Medicines increased, driven by strong HIV and Oncology ...

Hopkins residents Anthony Modrow, 34, and Rachel Modrow, 34, were both charged with second-degree manslaughter for their ...

LABAs should be used only with other medications. Two products that combine a LABA and an inhaled steroid (Advair and Symbicort) should be used for the shortest time possible to reduce the chance ...

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed ...

GSK said the decision will take effect by Jan. 1, 2025. The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, ...

Consider the example from the US of GlaxoSmithKline’s Advair (seretide) formulation, which came off patent in 2010 [although integration as part of the Diskus delivery device extended the patent ...

Canasa rectal suppositories and Advair Diskus. The suit was filed by Kessler Topaz Meltzer & Check, Carella Byrne Cecchi Olstein Brody & Agnello and Young Law Group. Counsel have not yet appeared ...

Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15–25% of the ...